Administration of CORM-2 inhibits diabetic neuropathy but does not reduce dyslipidemia in diabetic mice

Karen Alejandra Méndez-Lara, David Santos, Núria Farré, Sheila Ruiz-Nogales, Sergi Leánez, José Luis Sánchez-Quesada, Edgar Zapico, Enrique Lerma, Joan Carles Escola-Gil, Francisco Blanco-Vaca, Jesús Maróa Martón-Campos, Josep Julve, Olga Pol

Research output: Contribution to journalArticleResearch

2 Citations (Scopus)

Abstract

© 2018 Méndez-Lara et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. The antinociceptive effects of the carbon monoxide-releasing molecule tricarbonyldichlororuthenium (II) dimer (CORM-2) during chronic pain are well documented, but most of its possible side-effects remain poorly understood. In this work, we examine the impact of CORM- 2 treatment on the lipoprotein profile and two main atheroprotective functions attributed to high-density lipoprotein (HDL) in a mouse model of type 1 diabetes while analyzing the effect of this drug on diabetic neuropathy. Streptozotocin (Stz)-induced diabetic mice treated with CORM-2 (Stz-CORM-2) or vehicle (Stz-vehicle) were used to evaluate the effect of this drug on the modulation of painful diabetic neuropathy using nociceptive behavioral tests. Plasma and tissue samples were used for chemical and functional analyses, as appropriate. Two main antiatherogenic properties of HDL, i.e., the ability of HDL to protect low-density lipoprotein (LDL) from oxidation and to promote reverse cholesterol transport from macrophages to the liver and feces in vivo (m-RCT), were also assessed. Stz-induced diabetic mice displayed hyperglycemia, dyslipidemia and pain hypersensitivity. The administration of 10 mg/kg CORM-2 during five consecutive days inhibited allodynia and hyperalgesia and significantly ameliorated spinal cord markers (Cybb and Bdkrb1expression) of neuropathic pain in Stz mice, but it did not reduce the combined dyslipidemia shown in Stz-treated mice. Its administration to Stz-treated mice led to a significant increase in the plasma levels of cholesterol (∗1.4-fold vs. Ctrl,∗1.3- fold vs. Stz-vehicle; p < 0.05) and was attributed to significant elevations in both non-HDL (∗1.8-fold vs. Ctrl;∗1.6-fold vs. Stz-vehicle; p < 0.05) and HDL cholesterol (∗1.3-fold vs. Ctrl,∗1.2-fold vs. Stz-vehicle; p < 0.05). The increased HDL in plasma was not accompanied by a commensurate elevation in m-RCT in Stz-CORM-2 compared to Stz-vehicle mice; instead, it was worsened as revealed by decreased [3H]-tracer trafficking into the feces in vivo. Furthermore, the HDL-mediated protection against LDL oxidation ex vivo shown by the HDL isolated from Stz-CORM-2 mice did not differ from that obtained in Stz-vehicle mice. In conclusion, the antinociceptive effects produced by a high dose of CORM-2 were accompanied by antioxidative effects but were without favorable effects on the dyslipidemia manifested in diabetic mice.
Original languageEnglish
Article numbere0204841
JournalPLoS ONE
Volume13
DOIs
Publication statusPublished - 1 Oct 2018

Fingerprint Dive into the research topics of 'Administration of CORM-2 inhibits diabetic neuropathy but does not reduce dyslipidemia in diabetic mice'. Together they form a unique fingerprint.

Cite this